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Consider these real-life scenarios:
w Two HIV-infected inmates (one also infected
with hepatitis B) shared injecting-drug needles
with at least 104 inmates in an Australian prison.
w A male inmate was repeatedly sexually
assaulted by a prisoner who was known to be
HIV- and hepatitis C-infected.
w A male inmate reported having unprotected,
anal receptive consensual sex with someone of
unknown hepatitis and HIV status.
w A female inmate was stuck by a needle she
found while cleaning a bathroom.
How should these blood or body fluid exposures
be managed in the correctional setting, and what
are the infections of concern? Are correctional
professionals prepared to manage these expo-
sures?  
HIV transmission is believed to be a rare conse-
quence of blood or body fluid exposures in the
correctional setting. However, if transmission
occurs, the consequences are permanent and
potentially deadly. Likewise, hepatitis C and
hepatitis B transmission can lead to lifelong illness
and sometimes a shortened life expectancy.
Fortunately, post-exposure interventions that
might reduce the transmission risk, and thereby
diminish the consequences of an exposure, do
exist and appear to be effective. 
Post-exposure prophylaxis (PEP) protocols that
incorporate such interventions have been imple-
mented in many settings, particularly for health
care staff. However, few correctional institutions
have implemented blood or body fluid post-expo-
sure protocols for inmates exposed to bloodborne
pathogens by any route (injection-drug use, con-
sensual sex, or sexual assault). This deficit is
especially noteworthy given recent calls for PEP
implementation in jails and prisons.1,2 Given the
acceptance of PEP outside the correctional set-
ting, adoption of PEP protocols in the correctional
setting may help reduce the legal, emotional, and
medical ramifications of an exposure event for this
vulnerable population.
Of course, prevention of blood or body fluid expo-
sures is preferable over post-exposure interven-
tions since such post-hoc measures are not com-
pletely effective, are costly, and carry the potential
for adverse side effects. However, not all expo-
sures can be prevented, particularly in jails and
prisons. It therefore is advisable that both pre- and
post-exposure bloodborne pathogen transmission
preventive measures be enacted in correctional
settings. 
In this article we discuss the management of PEP
for incarcerated individuals. Of course, the same
principles also apply to the management of a post-
exposure intervention for correctional staff. The
risk for transmission of three common bloodborne
infections - HIV, hepatitis B (HBV) and hepatitis C
(HCV) - is reviewed, as well as PEP options for
potential exposures to these pathogens. 
Transmission Risk
Bloodborne pathogen transmission depends upon
the nature of the exposure and the infectious sta-
tus of the exposure source. Prisoners are at risk
for HIV, HBV, and HCV infections from sexual con-
tacts, medical percutaneous injuries, and inject-
ing-drug paraphernalia sharing. The transmission
risk from these events is influenced by the amount
of infectious material involved, the characteristics
of the event, and the severity of the exposure
source's illness.  
The risk of infection following a given blood or
b dy fluid exposure depends first and foremost
upon the likelihood that the exposure source is
infected. In the correctional setting, the likelihood
of the source being infected with HIV, HBV or HCV
is higher than outside the prison walls.
Correctional professionals are familiar with the
high prevalence of HIV, HCV, and HBV in inmate
populations, ranging as high as 3% for HIV (and
up to 8.5% in some state prison systems3) and
35% for HCV.4,5 Data have recently been released
from  the Maryland AIDS Administration announc-
ing that one in three prison inmates in Maryland is
infected with HIV, syphilis, HBV, or HCV - many
having more than one infection.6
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Hepatitis B, C, and HIV Post-exposure
Prophylaxis in Correctional Settings
Transmission Estimates
HIV Transmission
HIV transmission estimates vary by the type
of exposure. Per-event transmission probabil-
ity estimates are 0.3% - 0.4% after a percuta-
neous (e.g., needlestick) exposure, and
0.09% after a mucous membrane exposure.8
The risk for HIV transmission per episode of
intravenous needle or syringe sharing is esti-
mated at 0.7%.7 The risk for HIV transmission
per episode of receptive penile-anal sexual
intercourse is estimated at 0.1% - 3%, while
the risk per episode of receptive vaginal inter-
course is estimated at 0.1% - 0.2%. No pub-
lished estimates of the risk for transmission
from receptive oral exposure exist, but
instances of suspected transmission have
been reported.7
These estimates are approximate, and
depend upon other factors, such as the stage
of HIV disease of the exposure source, the
presence of other sexually transmitted dis-
eases, and effective use of antiretroviral med-
ication with suppression of viral load.
According to Centers for Disease Control and
Prevention (CDC) PEP guidelines, several
factors could affect the risk of HIV transmis-
sion after exposure. The risk is increased
after an exposure to a large quantity of blood
from the source (e.g., a device visibly conta-
minated with blood, a procedure that involved
a needle being placed directly in a vein or
artery, a deep injury, etc.), as well as from
exposure to a source with an advanced HIV
infection (i.e., a high viral load).8
HBV Transmission
According to the CDC, the risk of HBV infec-
tion is primarily related to the degree of con-
tact with blood and the hepatitis B e antigen
(HBeAg) status of the source.8 Exposures to
sources harboring HBeAg confer a greater
risk of HBV transmission. In studies of health
care workers who sustained injuries from
needles contaminated with blood positive for
both HBsAg and HBeAg, the risk of develop-
ing clinical hepatitis was 22% - 31% and the
risk of serologic evidence of HBV infection
was 37% - 62%. In comparison, the risk of
developing clinical hepatitis from a needle
contaminated with HBsAg-positive, HBeAg-
negative blood was 1% - 6%, while the risk of
developing serologic evidence of HBV infec-
tion was 23% - 37%.8,9
The highest risk for transmission of HBV is
through exposure to blood, although saliva,
semen, sweat, feces, and bile may contain
infectious particles. However, most body flu-
ids contain low quantities of infectious HBV,
and are therefore not efficient transmitters of
infection.8
HCV Transmission
Although less well understood, HCV is likely
transmitted in the same manner as HIV and
HBV.10 Transmission rarely occurs from
mucous membrane exposures to blood, and
rarely, if at all, after percutaneous exposures
to blood with needles that are not hollow bore.
The risk for transmission from exposure to flu-
ids or tissues other than HCV-infected blood
has not been quantified, but is expected to be
low. The average risk of anti-HCV serocon-
version after an accidental percutaneous
exposure to an HCV-infected source is 1.8%,
with a range of 0%-7%.8
PEP Options
HIV PEP
HIV PEP involves two or three antiretroviral
medications that are begun no later than 72
hours after a potential HIV exposure (within
24 hours is best) and taken for 28 days.11,12
HIV PEP efficacy, although not proven
through randomized, placebo-controlled tri-
als, is suggested from clinical trials that
showed a reduction of perinatal HIV preven-
tion with antiretroviral medications use, ani-
mal studies which employed various chemo-
prophylactic regimens, immunologic investi-
gations on HIV transmission mechanisms,
and a multi-national observational study of
health care workers demonstrating
decreased HIV transmission among those
who took zidovudine after a percutaneous
injury.13
For more detail on the management of occu-
pational blood exposures to HIV, see the
HEPPigram on page 5. 
The CDC currently only endorses HIV PEP
for health care workers who have been possi-
bly exposed to HIV at their workplace.7,8 A
number of other groups in the US and else-
where have created their own HIV PEP rec-
ommendations or guidelines for people who
are not health care workers and have sus-
tained so-called "nonoccupational" exposures
to HIV, such as from sexual contact or inject-
ing-drug use.2,14,15 California and New York
have statewide guidelines on HIV PEP after
sexual assault, Massachusetts has a clinical
advisory on HIV PEP, and Rhode Island has
Department of Health-endorsed guidelines on
HIV PEP provision after all types of potential
HIV exposures.16,17,18,19New York is expected
to release similar comprehensive HIV PEP
guidelines soon, and the CDC is considering
recommendations for nonoccupational PEP.
HBV PEP
The CDC recommends vaccinating any non-
immune person who is potentially exposed to
hepatitis B from any type of transmissible
event.5,20 The CDC reserves hepatitis B
immunoglobulin for unvaccinated individuals,
and those who failed to respond serologically
to HBV vaccine who are then exposed to
infectious body fluids from someone with
known or suspected hepatitis B infection.
Although the efficacy of HBV PEP has not
been validated by randomized, blinded,
placebo-controlled trials, HBV PEP
experiments using vaccinations and/or
immunoglobulin infusions in the perinatal and
occupational settings provide strong evidence
suggesting efficacy.8 
Management of HBV exposure involves
determining the HBV status of the source, if
the source is known. Treatment of the
exposed individual can be delayed for up to
three days until this information is available. 
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Exposure type
Percutaneous injury, less
severe (e.g., solid needle 
or superficial injury)
Percutaneous injury, more
severe (e.g. large-bore hol-
low needle, deep puncture)
Mucous membrane expo-
sures and nonintact skin*
exposures, small volume
(i.e., a few drops)
Mucous membrane expo-
sures and nonintact skin*
exposures, large volume
(i.e., major blood splash)
Asymptomatic HIV
infection or known
low viral load
(<1,500 copies/mL)
2-drug PEP
3-drug PEP
2-drug PEP
2-drug PEP
Symptomatic HIV
infection, AIDS,
acute seroconver-
sion, or known
high viral load
3-drug PEP
3-drug PEP
2-drug PEP
3-drug PEP
Unknown HIV
status or
unknown source
2-drug PEP 
2-drug PEP
2-drug PEP
2-drug PEP
TABLE 1: Occupational HIV PEP**
Source infection status
*For skin exposures, follow-up is indicated only if there is evidence of compromised skin integrity
( .g., dermatitis, abrasion, or open wound).
**Some state departments of health (DOH) have published alternative guidelines. Consult with
your local DOH to see whether state-level guidelines exist.  
Table adapted from the Centers for Disease Control and Prevention, MMWR 2001, Vol. 50, No.
RR-11.
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Dear Correctional Colleagues:
True or False?
1. Many incarcerated injection drug users (IDUs) who don't have access to drug treatment or nee-
dle exchange will continue to share needles while in jail or prison. 
2. Although the "war on drugs" has led to a dramatic increase in the number of incarcerated IDUs,
few of these inmates have access to drug treatment while in jail or prison.
3. Correctional officers, janitorial and medical staff, and others working in jails and prisons are
regularly stuck with needles discarded by inmates who don't have access to needle exchange or
drug treatment. 
4. The Centers for Disease Control and Prevention endorses needle exchange as one compo-
nent of an effective drug policy.
5. Many inmates will have unprotected sex while incarcerated.
6. Condoms are known to be highly effective in preventing the transmission of HIV and other sex-
ually transmitted diseases. 
7. Jails and prisons that have made condoms available to inmates have had few or no discipli-
nary problems associated with condom distribution and use.
Answers:
1: True    2: True     3: True     4: True     5: True     6: True 7. True
Because most of us who practice medicine in correctional facilities are currently prohibited from
providing our patients the tools for PREP (pre-exposure prevention), it is our responsibility to be
well versed in PEP (post-exposure prophylaxis) for potential bloodborne pathogen exposures. In
this month's HEPP Report, Drs. Anne De Groot and Roland Merchant provide an excellent
overview of this important topic. It is my hope that some day harm reduction measures will be so
fully integrated into correctional health maintenance programs that the information contained in
this month's main article will be mostly of historical interest.
Also this month, Dr. Chris Behrens provides the expert response to a PEP case provided by Kate
Willner and Dr. Stephen Tabet. After reading this issue, you will have a better understanding f
the infectious risks associated with various blood and body fluid exposures, and be familiar with
the recommended management of individuals who have been exposed to blood borne
pathogens.
Sincerely yours, 
Joseph Bick, M.D.
Letter from the Editor
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4All correctional employees should be vacci-
nated against HBV. The CDC also recently
recommended that susceptible inmates be
vaccinated as well. Vaccinating inmates in
prisons has been demonstrated to be feasible
and cost-saving from both the prison and
community perspectives.5
HCV PEP
The CDC does not currently recommend any
form of HCV post-exposure prophylaxis fol-
lowing potential HCV exposures. However, if
acute HCV infection is confirmed in the
exposed person, recent data suggest that
early treatment of the acute infection with
alpha interferon may be highly effective in
preventing the development of chronic HCV
infection.21 Therefore, individuals who are
exposed to HCV should be referred to experi-
enced clinicians who can provide updated
counseling and treatment. 
PEP Experience in the
Correctional Setting
A recent article published in the Medical
Journal of Australia describes a cohort study
conducted in two Australian prisons involving
HIV, HBV, and HCV transmission and PEP.1
Two inmates infected with HIV and HCV (one
of whom also had chronic HBV), and more
than 100 inmates who shared needles and
syringes with either of the two were followed
in this study.
The two source patients (in two different pris-
ons) informed the staff at their respective
medical clinics that they had shared needles
with other injecting-drug users within the pre-
vious weeks. One inmate identified his shar-
ing partners, while the other inmate did not.
Inmates in both prisons who may have shared
needles with the source cases were contact-
ed and were invited to attend the prison clinic
if they had shared needles or syringes during
a specified period (the period of possible con-
tact with the source patients). One hundred
and seventy inmates attended the clinic in
response to the invitation, and 104 inmates
were determined to be potentially exposed. 
Of the 104 inmates potentially exposed to
HIV, 56 had been exposed within the previous
72 hours and were therefore eligible based
upon the prison's protocol for post-exposure
prophylaxis (PEP). Forty-six inmates (82% of
those eligible) were offered PEP, and 34 of
these (74%) elected to receive it. Thirty-four
men took PEP with zidovudine (AZT) and
lamivudine (3TC) for an average of 18 days.
Some trading of PEP drugs was reported
amongst prisoners and as a result prison
health staff began administering PEP as
directly observed therapy (DOT). Only eight
(24% of the 34) completed the full PEP
course of 28 days.  Among the 26 inmates
who did not complete the full course of PEP,
11 did not give a reason for stopping, though
some discontinuation occurred when the
inmates were transferred or released. The
authors conclude that another reason for
stopping therapy may have been the use of
DOT, instituted after the pill trading was dis-
covered. 
No cases of HIV infection were found at fol-
low-up testing a year later. However, only
61% of the 104 potentially exposed prisoners
received follow-up testing, and the
researchers acknowledged that seroconver-
sions might have occurred among those lost
to follow-up.
Inmates susceptible to HBV infection at base-
line received HBV vaccination or
immunoglobulin and no new cases of HBV
were detected during follow-up.
While only 29 men were susceptible to HCV
infection at baseline, four (14%) of these were
found to be infected with hepatitis C at follow-
up testing. Researchers were reluctant to
attribute these HCV seroconversions to the
documented exposures due to multiple expo-
sures and ongoing risk behaviors by the pris-
oners involved. Nevertheless, they concluded
that their findings are consistent with the high-
r probability of transmitting HCV compared
with HIV through sharing needles and
syringes. 
Conclusion
Many correctional facilities have adopted PEP
guidelines for the management of staff
needlestick and sharp exposures.
Nonoccupational PEP is a newer concept that
has been implemented in community settings.
As described in the report from Australia,
inmates can be exposed to HIV, HCV and
HBV in correctional settings. Thus, familiarity
with  post-exposure preventive prophylaxis is
an important aspect of medical care in correc-
tional settings, both for inmates and staff who
may become exposed to HIV, HBV or HCV in
the course of their work. Despite the best
efforts of correctional staff, it is likely that
exposures will continue to occur. The best
prevention is good preparation. 
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Vaccination and
antibody response
status of exposed
workers*
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Management of Occupational Blood Exposure
1. Provide immediate care to the exposure site.
w Wash wounds and skin with soap and water.
w Flush mucous membranes with water.
2. Determine risk associated with exposure by
w type of fluid (e.g., blood, visibly bloody fluid, other potentially infectious fluid 
or tissue, and concentrated virus) and
w type of exposure (i.e., percutaneous injury, mucous membrane or nonintact 
skin exposure, and bites resulting in blood exposure).
3. Evaluate exposure source.
w Assess the risk of infection using available information.
w Test known sources for HBsAg, anti-HCV, and HIV antibody (consider 
using rapid testing). 
w For unknown sources, assess risk of exposure to HBV, HCV, or HIV 
infection.
w Do not test discarded needles or syringes for virus contamination.
4. Evaluate the exposed person.
w Assess immune status for HBV infection (i.e., by history of hepatitis B 
vaccination and vaccine response).
5. Give PEP for exposures posing risk of infection transmission.
w HBV: See Table 2 (page 4).
w HCV: PEP not recommended.
w HIV: See Table 1 (page 2). 
w Initiate PEP as soon as possible, preferably within hours of exposure.
w Offer pregnancy testing to all women of childbearing age not known to 
be pregnant. 
w Seek expert consultation if viral resistance is suspected.
w Administer PEP for four weeks if tolerated.
6. Perform follow-up testing and provide counseling.
w Advise exposed persons to seek medical evaluation for any acute illness 
occurring during follow-up.
HBV exposures
w Perform follow-up anti-HBs testing in persons who receive hepatitis B 
vaccine.
w Test for anti-HBs 1-2 months after last dose of vaccine.
w Anti-HBs response to vaccine cannot be ascertained if HBIG was 
received in the previous 3-4 months. 
HCV exposures
w Perform baseline and follow-up testing for anti-HCV and alanine 
aminotransferase (ALT) 4-6 months after exposures.
w Perform HCV RNA at 4-6 weeks if earlier diagnosis of HCV 
infection desired.
w Confirm repeatedly reactive anti-HCV enzyme immunoassays (EIAs) with 
supplemental tests. 
HIV exposures
w Perform HIV-antibody testing for at least 6 months postexposure (e.g., at 
baseline, 6 weeks, 3 months, and 6 months). 
w Perform HIV antibody testing if illness compatible with an acute retroviral 
syndrome occurs.
w Advise exposed persons to use precautions to prevent secondary 
transmission during the follow-up period.
w Evaluate exposed persons taking PEP within 72 hours after exposure and 
monitor for drug toxicity for at least 2 weeks.
w Monitor patients for signs of acute retroviral syndrome. In the event that 
acute retroviral syndrome occurs, patients should begin immediate 
antiretroviral therapy. 
6Discussion: What should the emergency department physician
initially do with the assaulted inmate?
The ED physician should first ensure that the assaulted inmate is med-
ically stable. This includes ruling out ongoing bleeding or colonic per-
foration from the assault. Any mucosal or skin tears should be prompt-
ly irrigated in sterile fashion. A forensics examination kit can be used
to collect specimens that may be required for legal evidence of the
assault, but this should not delay decontamination procedures.
What type of testing should be done, and when?
Initial Tests
Initial serology testing: Baseline serum testing of the assaulted inmate
for antibodies to HIV and HCV is indicated, as well as a battery of HBV
tests to establish his HBV status (immune, non-immune, or chronical-
ly infected). The HBV tests should include hepatitis B surface antibody
(HBsAb), hepatitis B surface antigen (HBsAg), and hepatitis B core
antibody (HBcAb). These tests should be performed before HBV post-
exposure prophylaxis (PEP) is administered. 
Baseline labs:A baseline complete blood count (CBC), an electrolyte
panel, and liver function tests should also be performed if the assault-
ed inmate is to begin antiretroviral prophylaxis against HIV. 
Cultures:Rectal cultures should be obtained for gonorrhea and
chlamydia. Testing of the source inmate or patient  should be per-
formed, if possible (consent may be required), and should include HIV
antibody testing, a serum rapid plasma reagin (RPR) to screen for
syphilis, and gonorrhea and chlamydia testing (by urine ligase chain
reaction [LCR] testing). Any genital lesions present on the source
patient should be cultured as well.
Follow-up Tests
HIV: Follow-up HIV antibody testing for the assaulted inmate is indi-
cated if the source patient is tested and found to be infected with HIV,
or if the source patient cannot be tested for HIV. Some clinicians might
argue in favor of performing this follow-up testing on the assaulted
inmate even if the source patient tests negative for HIV at the time of
the exposure, given the theoretical possibility that the source patient
could be in the "window period" of acute HIV infection prior to antibody
seroconversion. 
HIV antibody testing performed at six weeks, three months, and six
months is a reasonable schedule for follow-up testing and is recom-
mended for occupational percutaneous exposures to HIV.1 Case
reports of delayed HIV seroconversion in health care personnel who
became coinfected with HIV and HCV from percutaneous exposures2,3
have prompted recommendations to consider HIV antibody testing at
12 months post-exposure in health care personnel who contract HCV
from co-infected patients.4 If it is established that the source patient in
this case is co-infected with HCV and HIV, and the assaulted inmate
contracts HCV from the exposure, it would be reasonable to apply this
reasoning to the present case, and perform HIV antibody testing at 12
months as well. HIV RNA polymerase chain reaction (PCR) testing
("viral load") would be indicated only if the source patient is found to
be HIV-infected and the assaulted inmate develops signs and symp-
toms consistent with acute HIV infection. 
If the assaulted inmate initiates antiretroviral PEP for HIV, as recom-
mended below, then follow-up CBC, electrolyte panel, and liver func-
tion tests should be performed two weeks later to monitor potential
edication-related toxicities.
Hepatitis B:If baseline HBV serologies suggest that the assaulted
inmate is 1) currently not infected with hepatitis B; and 2) not immune
to hepatitis B infection, then follow-up testing for hepatitis B serocon-
version is indicated. Specific guidelines for this scenario are lacking,
but a reasonable approach would be to test for HBsAg periodically. A
recommended schedule is six weeks, twelve weeks, and six months,
the same schedule that would be followed for HIV antibody testing,
and as suggested by any clinical signs/symptoms of acute hepatitis. 
Hepatitis C:Follow-up testing will be required for HCV, though sexual
exposure does not appear to be an efficient mechanism for transmit-
ting HCV. The Centers for Disease Control and Prevention (CDC) rec-
ommends testing for hepatitis C antibody four to six months following
percutaneous occupational exposure, and this would be a reasonable
standard to use in this case. Simultaneous alanine aminotransferase
(ALT) testing can be performed, though this is a less reliable marker of
HCV infection. If hepatitis C antibody seroconversion occurs, referral
for further testing and medical management is indicated, which would
include a HCV viral load for confirmatory testing and a discussion of
treatment options if the inmate develops chronic hepatitis C infection. 
Would you recommend PEP? Why or why not?
I w uld recommend PEP for HIV and HBV in this situation. Empiric
tre tment of possible gonorrhea and chlamydia infection should also
be considered.
Rationale for HIV PEP
I would consider the source patient (the assailant) to be at high risk for
HIV infection given he is known to be infected with both HBV and HCV,
both of which share similar routes of transmission as HIV (sex and
IDU). For the assaulted inmate, this type of exposure itself is very high
risk: a single act of unprotected receptive anal intercourse involving an
HIV-infected source patient carries a risk estimated at 1-2% for HIV
transmission.5 Furthermore, this case involved rape, and the violence
associated with acts of rape often results in tearing of the rectal
mucosa, which could be expected to further elevate the risk of HIV
transmission.
Treatment Recommendations
I would recommend an expanded three-drug PEP regimen such as
zidovudine + lamivudine + nelfinavir (AZT + 3TC + NFV). I suggest the
nucleoside backbone of AZT + 3TC because AZT has demonstrated
effic cy for PEP in the setting of health care workers who have sus-
tained percutaneous needlestick injuries.6 As we have no conclusive
evidence regarding the efficacy of PEP for sexual exposures in
humans, we can only extrapolate from what is known about PEP for
occupational exposures. We add 3TC because PEP regimens gener-
ally include at least two drugs and because 3TC is generally very well
olerated. The addition of a third drug in this case, such as NFV, is a
bit m re controversial. We actually have no evidence that adding a
third drug to a standard two-drug PEP regimen offers any added pro-
tection against HIV infection, even in the setting of an occupational
Case presentation by Stephen Tabet*, M.D., M.P.H., Assistant Professor of Medicine, University of Washington, and Director, Northwest Correctional
Medicine Education Program. Case discussion by Chris Behrens**, M.D., Medical Program Director, Northwest AIDS Education & Training Center,
University of Washington. A collaboration with the Northwest AIDS Education and Training Center, with Stephen Tabet, M.D., and Kate Willner, trainer.
Ask the Expert
Case Study: Post-Exposure Prophylaxis for a Sexually Assaulted Male Inmate
(Continued on page 7)
Case: An inmate reports being raped (anally penetrated) by another inmate and is sent to a local emergency department (ED) within two
hours after the assault. The assaulted inmate denies any past or current injection drug use (IDU) or sex with men (except the assault) and
recently tested negative for HIV infection; the hepatitis B virus (HBV) and hepatitis C virus (HCV) serostatus is unknown. The assailant is a
previous injection drug user. He is known to have chronic HBV and HCV infection, however his HIV status is unknown.
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percutaneous exposure; furthermore, adding a third agent generally
adds more potential for antiretroviral medication-related toxicities.7
On the other hand, drawing from our experience in treating chronic
HIV infection, we recognize that three agents may be more effective
than two in suppressing HIV infection, and NFV is a relatively benign
protease inhibitor whose main side effect - diarrhea - can generally be
controlled with anti-diarrheal agents. Hence, I would recommend a
three-drug PEP regimen, while recognizing the relative paucity of evi-
dence to support this recommendation. Should the patient experience
intolerable side effects from the NFV, discontinue this agent, and sub-
stitute either a different third agent, for example indinavir (IDV), or sim-
ply continue the basic AZT/3TC regimen without a third agent.
Ideally, the source patient would be tested for HIV infection. Should he
test negative, PEP for the assaulted inmate should be discontinued. If
the source patient tests positive, however, PEP should be continued
for a total of 28 days, followed by periodic HIV antibody testing as out-
lined above.
HBV PEP
Because the source patient is known to have chronic hepatitis B infec-
tion, this exposure places the assaulted inmate at risk of contracting
hepatitis B, unless he is already immune. However, we currently have
no evidence that he is immune to hepatitis B. I would therefore rec-
ommend HBV PEP, including 1) hepatitis B immune globulin (HBIG);
and 2) initiation of the HBV vaccination series. Each should be given
as soon as possible (though after baseline hepatitis B serologies are
drawn, as outlined above). These two injections can be administered
simultaneously but they should be administered at different sites on
the body. It is believed, based on evidence from postpartum neonatal
prophylaxis studies to prevent vertical transmission8,9 that the addition
of HBV vaccination to the use of HBIG following potential exposure to
HBV further reduces the risk of HBV infection. This is the same man-
agement that would be indicated for an unvaccinated health care work-
er who has sustained a percutaneous occupational exposure to a
patient with chronic HBV infection.10 If baseline hepatitis B serologies
indicate that the assaulted inmate is not immune to hepatitis B infec-
tion, the vaccination series should be continued. Six to eight weeks
after the last injection of this three-shot vaccination series, a surface
antibody titer can be checked to see if the vaccine elicited a protective
antibody response. 
HCV PEP
There is currently no recommended post-exposure prophylaxis to pre-
vent HCV infection.  Recent data suggest that early treatment (within
four months) of acute hepatitis C infection with interferon may sub-
stantially increase the likelihood of successful eradication over that
historically seen with treatment of chronic hepatitis C infection.11 For
this reason, some clinicians might favor screening the exposed patient
with HCV RNA PCR (viral load) tests periodically, e.g. on a monthly
basis, and initiating interferon therapy if HCV viremia is detected.
However, given the potential toxicity of interferon, the fact that a sig-
nificant minority of patients spontaneously clear HCV viremia without
therapy, and the possibility that waiting for six months may not jeopar-
dize a favorable response to treatment, other clinicians might favor
simply screening six months following the exposure. More evidence is
needed before definitive recommendations can be made regarding
arly screening and treatment of acute hepatitis C infection.
Gonorrhea and Chlamydia PEP
It may be appropriate to offer treatment for gonorrhea and chlamydia
to the assaulted inmate, especially if physical examination of the
assailant suggests the presence of either of these sexually transmitted
diseases. If, however, the source patient can be tested for these infec-
tions, it would also be reasonable to defer the treatment decision until
the results of these tests are known, given that follow-up care of the
assaulted inmate can be guaranteed in this setting. 
As the above case illustrates, the management of exposures to infec-
tious pathogens involving considerations of PEP can be complex.
Clinicians are reminded of telephone consultation services such as the
National Clinicians' Post-Exposure Prophylaxis Hotline (PEPline),
available 24 hours a day/7 days a week, at 1-888-HIV-4911.
DISCLOSURES:
*Nothing to disclose.
** Speaker's Bureau, GlaxoSmithKline.
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Case Study... (continued from page 6)
w PEPline: National Clinicians' Post-exposure Prophylaxis
Hotline:1-888-448-4911
w CDC Guidelines on HIV, HBV, and HCV Occupational PEP:
www.cdc.gov/mmwr/preview/mmwrhtml/rr5011a1.htm
w CDC Public Health Statement on Nonoccupational PEP:
www.cdc.gov/mmwr/preview/mmwrhtml/00054952.htm
w National Institute for Occupational Safety and Health:
www.cdc.gov/niosh/topics/bbp/
w National HIV/AIDS Clinicians' Consultation Center, PEP
Resources: www.ucsf.edu/hivcntr/resources/pep/
w CDC Nonoccupational HIV PEP Registry:
www.hivpepregistry.org
w Nonoccupational HIV PEP Guidelines for RI Health Care
Practitioners (Brown University AIDS Program and the RI
Department of Health):
http://www.brown.edu/Departments/BRUNAP/npepguid 
w NY State Occupational and Sexual Assault PEP Guidelines:
www.hivguidelines.org/public_html/center/clinical-guidelines/
pep_guidelines/pep_guidelines.htm
PEP Phone and Internet Resources
American Correctional
Association Summer
Conference
August 9-14, 2003
Nashville, Tennessee
Call: 800-222-5646, ext. 1922
Visit: www.aca.org/conventions/
conventions_2003_summer.htm
3rd Annual Intensive Review in
Correctional Medicine
Sponsored by the Correctional
Medicine Institute (CMI), the
Society for Correctional Physicians
(SCP), and Johns Hopkins Univ.
September 4-6, 2003
Baltimore, Maryland
Baltimore Marriott Waterfront Hotel
Call: 410-955-2959
Email: cmenet@jhmi.edu
Visit: www.hopkinscme.org/cme/
events/correc03.html
43rd Interscience Conference
on Antimicrobial Agents and
Chemotherapy (ICAAC)
September 14-17, 2003
Chicago, Illinois
Call: 202-737-3600
Email: icaac@asmusa.org
Visit: www.icaac.org/ICAAC.asp
The U.S. Conference on AIDS
Sponsored by the National
Minority AIDS Council
September 18-21, 2003
New Orleans, Louisiana
Call: 202-483-6622
Visit: www.nmac.org
HIV Minifellowship for
Correctional Health Care
Providers
Sponsored by the Univ. of Texas
Medical Branch and 
HEPP Report, Brown Univ.
September 22-24, 2003
Providence, Rhode Island
Call: 409-747-8769
Email: pwelsh@utmb.edu
National Conference on
Correctional Health Care 
October 4-8, 2003
Austin, Texas
Call: 773-880-1460
Visit: www.ncchc.org
41st Annual Meeting of
Infectious Disease Society of
America (IDSA)
October 9-12, 2003
San Diego, California
Call: 703-299-0200
Email: info@idsociety.org
Visit: www.idsociety.org
Save the 
Dates
8
FDA Approves Atazanavir, First Once-Daily PI
The FDA has approved Bristol-Myers Squibb's
(BMS) protease inhibitor Reyataz (atazanavir),
the first once-daily protease inhibitor (PI). The
once-a-day dose of two pills should be taken with
food. Unlike other PIs, atazanavir (ATZ) does not
appear to cause a rise in cholesterol. However,
atazanavir can cause hyperbilirubinemia leading
to jaundice or scleral icterus in up to 24% of
patients. This abnormality disappears when
patients stop taking ATZ, and, according to the
FDA, does not appear to be associated with liver
injury. BMS said ATZ will be available in July, but
did not disclose a price, saying only that it would
be competitive with other PIs. A sociated Press,
6/20/03
Patient History Card Available to HIV-infected
Inmates
Boehringer Ingelheim Pharmaceuticals, in con-
junction with several leading correctional physi-
cians, has launched the Patient History Card,
designed to help HIV-infected inmates manage
and monitor their HIV care both within prison and
on the outside. The card enables patients to
record current medications, viral loads, CD4+
counts, weight, drug allergies, vaccinations and
other information. "We designed the Patient
History Card as a foldable, wallet-sized card so
that HIV-positive inmates can carry it with them at
all times," said David Wohl, MD, assistant profes-
sor of medicine at the University of North
Carolina, who helped design the card. Patient
names and the words "HIV" and "AIDS" do not
appear anywhere on the cards. Cards are avail-
able free of charge to all correctional facilities in
the US by calling 1-877-933-4310 ext. 9527 or
9551. PRNewswire, 6/12/03
Save the Date: "Texas" Minifellowship
The annual HIV Minifellowship for Correctional
Health Care Providers will be held in Providence,
Rhode Island, on September 22, 23, and 24.
Sponsored by the University of Texas Medical
Branch and HEPP Report, the conference will
feature discussions by leading correctional care
providers and infectious disease specialists.
Topics will include HIV epidemiology, opportunis-
tic infections, HIV/HCV co-infection, mental
health issues, guidelines for initiating and modify-
ing ARV, and ethical issues. Call 409-747-8769
or email pwelsh@utmb.edu to register.
Enfuvirtide (Fuzeon) Effective in Patients
with Drug Resistance
Roche and Trimeris's new antiretroviral, Fuzeon
(enfuvirtide or T-20) doubles the chances that an
HIV-infected patient who has developed drug
resistance can achieve undetectable levels of the
virus, according to two studies published in the
May 29, 2003 issue of the New England Journal
of Medicine (NEJM). The NEJM published results
from the T-20 vs. Optimized Regimen Only Study
1 (TORO 1) and T-20 vs. Optimized Regimen
Only Study 2 (TORO 2). T-20 is administered via
twice daily subcutaneous injections. NEJM,
5/29/03
Court: NY State Did Not Improperly Deny
Inmate Treatment for HCV
The appellate division of the NY State Supreme
Court ruled that state prison administrators did
not improperly deny an inmate treatment for
hepatitis C, largely because the inmate failed to
undergo the substance abuse treatment prereq-
uisite and continued to abuse illegal drugs while
in prison.  While the inmate argued that refusal to
supply him with treatment constituted cruel and
unusual punishment, the court said that the
inmate didn't prove that there was "deliberate
indifference" on the part of prison officials, and
that the substance abuse program was a "rea-
sonable" prerequisite. Associated Press, 6/23/03
New Antibiotic Appears Effective Against
MDR TB
The antibiotic linezolid (Zyvox) may be an effec-
tive treatment for some strains of multidrug resis-
tant (MDR) tuberculosis (TB). Linezolid was used
to treat four people at New York City's Bellevue
Hospital who were infected with MDR TB when
all other available therapies failed to improve the
patients' health. The patients took linezolid twice
a day for 9-33 months, and four patients also
received interferon gamma three times a week.
Following treatment, there was no sign of TB in
patients' sputum. The NYU physicians who pre-
sented the cases at the 99th International
Conference of the American Thoracic Society in
Seattle said further studies are needed to confirm
their case reports. CDC Prevention News
Update, 6/11/03
Inside News
Resources
Tuberculosis: First Revised Guidelines Issued
Since 1994
www.cdc.gov/mmwr/preview/mmwrhtml/
rr5211a1.htm
www.thoracic.org/adobe/statements/treattb.pdf
The American Thoracic Society, CDC, and the
Infectious Diseases Society of America have
released their first completely revised TB preven-
tion, control, diagnosis and treatment guidelines
since 1994. The jointly developed guidelines, first
published in 1971, are intended to advise public
health programs and health care providers on all
aspects of the clinical and public health manage-
ment of TB in low-incidence countries. The new
guidelines focus on the latest aspects of therapy,
including drug administration, fixed-dose combi-
nation preparations, monitoring and managing
adverse effects, and drug interaction.
HIV Inmate Education Newsletter
CorrectHELP publishes a brief, easy-to-read
newsletter with HIV information for patient/
inmates four times a year, suitable for distribution
in custody. For more information and to receive
copies contact Ron Snyder at
ron@correcthelp.org or 323.822.3830.
New Quality Assurance Guidelinesfor Testing
Using the OraQuick Rapid HIV-1 Antibody Test 
ww.cdc.gov/hiv/rapid_testing/materials/QA_
Guidlines_OraQuick.pdf
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through January 31,2004. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. Following an exposure to a source known to be infected with
HBV, the CDC recommends hepatitis B immunoglobulin for:
(a) Previously vaccinated individuals.
(b) Previously unvaccinated individuals.
(c) Those who failed to respond serologically to HBV vaccine. 
(d) Previously vaccinated individuals and those who failed to 
respond serologically to HBV vaccine.
(e) Previously unvaccinated individuals and those who failed 
to respond serologically to HBV vaccine.
2. Per-event HIV transmission estimates after a percutaneous
(e.g., needlestick) exposure are between:
(a) 0.01% - 0.02%
(b) 0.3% - 0.4%
(c) 3.0% - 5.0%
(d) 30.0% - 40.0%
3. HIV transmission factors depend upon:
(a) The amount of blood involved.
(b) The source's use of antiretroviral medications.
(c) The source's viral load.
(d) The type of exposure (sexual, mucous membrane, 
percutaneous).
(e) All of the above.
4. Exposures to body fluids (such as saliva, semen, sweat, feces
and bile) can just as effectively transmit HIV, HCV and HBV as
exposures to blood:
(a) True
(b) False
5. Following a percutaneous exposure to blood from a person
known to be HCV-infected, the CDC recommends:
(a) Combination therapy (pegylated IFN and ribavirin) be 
initiated as soon as possible, preferably within 24 hours. 
(b) Anti-HCV immunoglobulin be administered intramuscularly
(c) HCV vaccination be initiated
(d) No immediate HCV post-exposure prophylaxis be 
undertaken. 
6. Which of the following statements is true?
(a) HIV post exposure prophylaxis should be administered 
for 21 days.
(b) The efficacy of HIV post exposure prophylaxis has been 
proven in randomized prospective placebo controlled trials.
(c) HIV post exposure prophylaxis probably has little benefit if 
begun more than 72 hours after the exposure.
(d) HIV post exposure prophylaxis should always include a 
protease inhibitor.
(e) HIV post exposure prophylaxis should never be given to 
pregnant women.
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
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HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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